Please select the option that best describes you:
Did the low rate of COPD exacerbations in the BOREAS cohort overall confound the results of the study?
Answer from: at Community Practice
I feel that the results are still very impressive despite this.
Sign in or Register to read more
Answer from: at Academic Institution
They met their primary and secondary endpoints. So while data might be more robust, dupilumab impacted the study.